[High-risk PTCA assisted by the Hemopump 14F: the Geneva experience]

The hemopump is a transvalvular, catheter-mounted, left ventricular assist device, intended for surgical placement via the femoral artery (hemopump 21 Fr. outer diameter). This device has demonstrated its ability to unload the left ventricle, leading to myocardial protection and haemodynamic stabilisation in patients with cardiogenic shock and those undergoing high-risk coronary angioplasty (PTCA). Since 1994, a new hemopump system (14 Fr. in external diameter, flow rates of 1.5-2.2 l/min) has been developed for percutaneous insertion. The aim of this study is to describe the immediate and mid-term results obtained during Hemopump 14 Fr. assisted high-risk PTCA.

Between September, 1993 and July, 1996, 8 males and 5 female patients (mean age 68.5 +/- 8.6 years) underwent Hemopump 14 Fr. supported high-risk PTCA.

Mean duration of hemopump assistance was 108 +/- 62 min. Hemopump support on maximum speed led to an increase of cardiac index from 2.0 +/- 0.3 to 2.2 +/- 0.5 l/min (p = 0.04) and a decrease of pulmonary wedge pressure from 17 +/- 8 to 14 +/- 8 mm Hg (p = 0.004). LDH increased (463 +/- 305 to 558 +/- 237 u/l-p = 0.05) and the platelet count remained stable (192,840 +/- 60,904 to 190,230 +/- 56,492/mm3). Successful balloon angioplasty was performed in all patients. There was no hospital mortality. Three patients (23%) required blood transfusion. During follow-up, 1 patient (7.7%) developed femoral artery occlusion necessitating surgical repair, and 3 patients (23%) died from cardiac causes 3, 9 and 14 months after the procedure.

The 14 Fr. Hemopump device may constitute a useful percutaneous mode of haemodynamic support for patients undergoing high-risk PTCA. The haemolysis it causes is mild and not clinically significant, but the hemopump is associated with a significant rate of local vascular complications. Recent improvements in interventional techniques and hardware have decreased the necessity for circulatory assistance during elective PTCA, even for very ill patients. Nevertheless, indications such as cardiogenic shock, the "bridge" period prior to heart transplantation and video-assisted minimally invasive cardiac surgery, or haemodynamic support of the right ventricle are the new applications of the hemopump.